WEKO3
インデックスリンク
アイテム
Harnessing allogeneic CD4+ T cells to reinvigorate host endogenous antitumor immunity
https://fmu.repo.nii.ac.jp/records/2002081
https://fmu.repo.nii.ac.jp/records/200208121e3791d-fc64-4cf9-bc11-acbd517c6f23
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
FksmJMedSci_69_p157.pdf (538.6 KB)
|
|
| Item type | デフォルトアイテムタイプ（フル）fmu(1) | |||||||
|---|---|---|---|---|---|---|---|---|
| 公開日 | 2023-11-22 | |||||||
| タイトル | ||||||||
| タイトル | Harnessing allogeneic CD4+ T cells to reinvigorate host endogenous antitumor immunity | |||||||
| 言語 | en | |||||||
| 作成者 |
Mochizuki, Kazuhiro
× Mochizuki, Kazuhiro
|
|||||||
| 権利情報 | ||||||||
| 権利情報Resource | https://creativecommons.org/licenses/by-nc-sa/4.0/ | |||||||
| 権利情報 | © 2023 The Fukushima Society of Medical Science. This article is licensed under a Creative Commons [Attribution-NonCommercial-ShareAlike 4.0 International] license. | |||||||
| 内容記述 | ||||||||
| 内容記述タイプ | Abstract | |||||||
| 内容記述 | Immune checkpoint blockade (ICB) therapies developed over the past decade have been among the most promising approaches for the treatment of patients with advanced cancers. However, the overall objective response rate of ICB therapy for various cancers remains insufficient. Hence, novel strategies are required to improve the efficacy of immunotherapy for advanced cancers. The graft-versus-tumor (GVT) effect, which reflects strong antitumor immunity, is known to occur after allogeneic hematopoietic stem cell transplantation (HSCT). The GVT effect is mainly caused by transplanted donor lymphocytes that recognize and react to distinct alloantigens on tumor cells. In contrast, transplanted allogeneic cells can, in some instances, induce endogenous antitumor immunity in recipients if the graft has been rejected. Because of this ability, allogeneic cells have also been used to induce endogenous antitumor immunity without HSCT, and their beneficial immune response is referred to as the "allogenic effect." Here, we review the usefulness of allogeneic cells, particularly allogeneic CD4+ T cells, in cancer immunotherapy by highlighting their unique potential to induce host endogenous antitumor immunity. | |||||||
| 出版者 | ||||||||
| 出版者 | The Fukushima Society of Medical Science | |||||||
| 言語 | ||||||||
| 言語 | eng | |||||||
| 書誌情報 |
en : Fukushima Journal of Medical Science 巻 69, 号 3, p. 157-165, 発行日 2023 |
|||||||
| 関連情報 | ||||||||
| 関連タイプ | isIdenticalTo | |||||||
| 識別子タイプ | DOI | |||||||
| 関連識別子 | https://doi.org/10.5387/fms.23-00001 | |||||||
| 関連情報 | ||||||||
| 識別子タイプ | PMID | |||||||
| 関連識別子 | 37880140 | |||||||
| 資源タイプ | ||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||
| 資源タイプ | journal article | |||||||
| 出版タイプ | ||||||||
| 出版タイプ | VoR | |||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||
| 収録物識別子 | ||||||||
| 収録物識別子タイプ | PISSN | |||||||
| 収録物識別子 | 0016-2590 | |||||||
| 収録物識別子 | ||||||||
| 収録物識別子タイプ | EISSN | |||||||
| 収録物識別子 | 2185-4610 | |||||||
| 収録物識別子 | ||||||||
| 収録物識別子タイプ | NCID | |||||||
| 収録物識別子 | AA0065246X | |||||||
